Articles from Acelot

Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with high unmet need, today announced that Acelot CMO & CDO Mark Forman, MD, PhD, will present preclinical data from the company’s TDP-43 program at the upcoming 2026 Annual Network of Excellence for ALS (NEALS) meeting, taking place October 27-30 in Clearwater, FL and virtually. Additionally, Acelot CEO Katie Planey, PhD, MBA, will participate in an industry roundtable discussing the advancement of TDP-43-relevant therapeutic targets.

Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with high unmet need, today announced the initiation of the Phase Ia clinical trial of ACE-2223 to evaluate its safety, tolerability, and pharmacokinetics in healthy adults. The first-in-class, orally bioavailable small molecule, ACE-2223, is designed to specifically bind to and disrupt aggregated TDP-43, a dysfunctional protein present in approximately 97% of sporadic ALS cases, with the goal of restoring normal TDP-43 function.

Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with limited treatment options, today announced the appointment of Mark Forman, M.D., Ph.D. as Chief Development Officer and Chief Medical Officer. Dr. Forman will oversee the company's clinical and development strategy as Acelot advances its pipeline of novel therapies targeting neurodegenerative diseases.